If you believe in innovative AI healthcare, these 3 stocks could define the next cycle

Artificial intelligence in healthcare stands at the crossroads of rising inflation pressures, rising bond yields, and ongoing geopolitical tensions as investors seek themes tied to real-world problem solving and efficiency. AI tools that help doctors detect disease, personalize treatment, and reduce hospital bottlenecks have a direct impact on cost control and improving patient outcomes, two priorities that tend to be important regardless of growth or rate cycles. In this article, we highlight three stocks from our Transformative AI Healthcare screener to learn more about companies that use data and algorithms to deliver diagnosis, treatment, and care at scale.

GeneDx Holdings (WGS)

overview: GeneDx Holdings is a genomics company providing whole exome and whole genome sequencing for pediatric and rare diseases. We use AI to analyze your DNA and provide clinical-grade test reports for rare diseases, genetic risks, and cancer. We also sell data and information services built on large rare disease datasets.

operation: GeneDx generates nearly all of its US$427.5 million in revenue in the US, with US$423.1 million coming from its core Gene Dx division and US$4.5 million from Fabric Genomics and legacy Sema4.

Market capitalization: 2 billion USD

GeneDx is at the center of AI-driven genomics in pediatrics, with whole exome and genome sequencing supported by rare disease databases and an AI platform aimed at making diagnosis faster and more accurate. Analysts expect strong sales and profit growth. The stock is currently well below some fair value estimates and price targets, which could be attractive to investors focused on false price growth. At the same time, the company is unprofitable, dependent on external funding, and experiencing insider sales, so redemption execution, volume growth, and cost discipline are critical. Recent transactions such as the Zevra NPC testing program and new term loan demonstrate how GeneDx is expanding its model and strengthening its finances.

AI-powered genomics, rare disease datasets, and stocks trading below some fair value estimates can create interesting mismatches. Learn how 3 major rewards and 1 important warning sign can change your view of hidden tradeoffs in GeneDx.

Pfizer (PFE)

overview: Pfizer, supported by partnerships with companies including Bristol-Myers Squibb, Astellas, Merck KGaA and BioNTech, is a global pharmaceutical company that discovers, develops, manufactures and markets prescription medicines and vaccines for conditions such as cardiovascular disease, migraine, cancer, rare diseases, infectious diseases, inflammation and COVID 19.

operation: Pfizer generates the majority of its US$62.2 billion revenue from its US$61.2 billion global biopharmaceutical business, with US$1.3 billion from Pfizer Centleone and US$41 million from Pfizer Ignite, and US$37.1 billion in U.S. revenue compared to US$25.5 billion across developed and emerging markets.

Market capitalization: $153.6 billion

Building on its broad portfolio of medicines and vaccines in areas such as oncology, rare diseases and metabolic health, Pfizer is enabling the experience of artificial intelligence in healthcare through the development of biomolecular AI models. The pipeline is busy, from obesity, GLP 1 programs, and oncology data at ASCO 2026 to priority reviews for Lyme disease vaccine candidates and cancer combinations. At the same time, the company is also grappling with questions about earnings and sales, dividend coverage and debt, which are expected to decline in the coming years. For investors considering factors such as AI-enabled R&D, late-stage assets, pricing pressures, and patent risk, the full story goes far beyond aggregate P/E ratios and high dividend yields.

Pfizer’s AI-driven R&D and broad drug portfolio may mask a very different risk-reward profile than its core earnings suggest. Check out the 1 major reward and 4 important warning signs (3 is important!) for you!

Insmed (INSM)

overview: Insmed develops and commercializes treatments for serious and rare diseases, with a focus on ARIKAYCE for refractory lung infections and a late-stage pipeline for bronchiectasis, pulmonary hypertension, Duchenne muscular dystrophy, amyotrophic lateral sclerosis, and other difficult-to-treat diseases in the United States, Europe, Japan and other regions.

operation: Insmed generates revenues of US$606.4 million from the development and commercialization of treatments for patients with rare diseases, including approximately US$453 million from the United States and US$153.5 million from international markets.

Market capitalization: $29.2 billion

Insmed sits at the intersection of AI-driven protein engineering and late-stage respiratory medicine. Expanded indications for brensocatib and Aricais are seen as key drivers, along with extensive research in gene therapy and pulmonary hypertension. Although analysts predict sales and earnings growth, the company is still in the red, has a very high P/S multiple, and is dependent on external funding and continued equity issuance, so the launch of brensocatib, payer access, and execution of Phase II and III readouts remain critical. For investors who can tolerate clinical, regulatory, and dilution risk, the combination of rare disease focus, operational continuity, and ambitious guidance for future respiratory revenue may make the company a stock to watch more closely as AI-driven drug development in complex lung diseases advances.

Insmed’s AI-driven breathing aids, focus on rare diseases, and high P/S valuation may tell a completely different story than the headlines suggest, and Insmed’s analyst predictions may reveal the twist investors are missing

The three stocks in this article are just a starting point. Our complete Transformative Artificial Intelligence (AI) Healthcare Stock Screen reveals 30 more AI healthcare stocks with equally compelling stories in diagnostics, drug discovery, and care delivery. By identifying and analyzing the companies offering the catalysts that best fit your vision of biomolecular AI, real-time monitoring, cost reduction, and accelerated clinical development, you can focus on the highest-conviction ideas available within Simply Wall Street.

Take control of your investment journey

If you think GeneDx Holdings or any of these companies is a great opportunity, sign up for free on Simply Wall St and add top picks to your watchlist to keep an eye on the stock price relative to fair value for an ideal entry point. Once migrated, manage your holdings with a portfolio command center that filters out the noise and delivers only the most important and actionable updates. Our community allows you to filter the best ideas from thousands of investor perspectives throughout your journey. Discover hidden catalysts and risks early to accelerate decision-making and stay ahead of the market.

Looking beyond today for fresh alternatives

New ideas don’t stay in the spotlight for long. Get in early as the best entry points are quickly captured as funds chase the next breakout.

• Scan for powerful profit strategies built to keep you paying, and use our 13 hand-picked dividend fortresses to find profit opportunities before everyone starts chasing dividends.
• We look for resilient stocks that can withstand downturns, select 73 resilient stocks with low risk scores, and identify companies with low risk scores while they still matter.
• Target future facing themes in physical infrastructure by examining 33 hand-picked power grid technology and infrastructure stocks to catch potential winners in grid technology before momentum really starts.

This article by Simply Wall St is general in nature. We provide commentary using only unbiased methodologies, based on historical data and analyst forecasts, and articles are not intended to be financial advice. This is not a recommendation to buy or sell any stock, and does not take into account your objectives or financial situation. We aim to provide long-term, focused analysis based on fundamental data. Note that our analysis may not factor in the latest announcements or qualitative material from price-sensitive companies. Simply Wall St has no position in any stocks mentioned.

Do you have feedback on this article? Interested in its content? Please contact us directly. Alternatively, email editorial-team@simplywallst.com.